Status:
WITHDRAWN
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
Lead Sponsor:
Galectin Therapeutics Inc.
Conditions:
Cancer of the Bile Duct
Gallbladder Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this clinical trial is to determine whether the combination of the established chemotherapeutic agent 5-fluorouracil(5-FU) and the large carbohydrate molecule GM-CT-01 is beneficial in ...
Detailed Description
Determine the overall response rate (ORR) defined as complete response (CR)rate plus partial response (PR) rate using Response Evaluation Criteria in Solid Tumors (RECIST), as well as the stable disea...
Eligibility Criteria
Inclusion
- 18 years of age or older.
- Histologically or cytologically documented carcinoma primary to the intra- or extra-hepatic biliary system or gall bladder with clinical and/or radiologic evidence of unresectable, locally advanced or metastatic disease.
- Prior neo-adjuvant or adjuvant therapy (including radiation therapy) is allowed provided it was completed at least 4 weeks before documented disease recurrence or metastasis.
- Discontinuation of radiation therapy at least 3 weeks prior to Day 1 of Cycle 1. Radiation therapy will not be allowed while a subject is on study except for palliative radiation therapy to non-target lesions administered following consultation with the Medical Monitor.
- Prior surgery must have been completed at least 14 days prior to Day 1 of Cycle 1.
- Nne or more measurable target lesion(s) according to RECIST. Measurable lesion(s) must be outside of previous radiation field or demonstrate clear radiographic progression on serial imaging if within previous treatment field.
- ECOG performance status less than or equal to 2.
- Life expectancy greater or equal to 3 months.
Exclusion
- Central nervous system metastasis.
- Bony metastasis as the sole metastasis.
- Received prior chemotherapy or anti-angiogenesis agents including bevacizumab or erbitux or radiation therapy other than in a neo-adjuvant or adjuvant setting. No concomitant chemotherapy, anti-tumor biologic therapy, or radiation therapy is allowed.
- If nitrosoureas or mitomycin C were used as neo-adjuvant or adjuvant therapy, then at least 6 weeks should have elapsed prior to treatment with DAVFU.
- Active infection that requires treatment with systemic antibiotic, anti- fungal. or anti-viral therapy.
- Congestive heart failure (Class III or IV in the NYHA functional classification system) or any other medical condition that would preclude the IV administration of up to approximately 200 mL of fluid over 30-60 minutes.
- Unresolved biliary tract obstruction.
- Known or clinically suspected infection with HIV.
- Subject has a known intolerance to 5- FU.
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00386516
Start Date
September 1 2006
End Date
June 1 2009
Last Update
August 1 2017
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Boston Medical Center
Boston, Massachusetts, United States, 02118
2
University of Michigan, Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109
3
Barrett Cancer Center
Cincinnati, Ohio, United States, 45267-0501